Gentian Diagnostics and Beckman Coulter Partner to Launch Gentian GCAL® Calprotectin Immunoassay

10 Mar 2025 12:44 CET

Moss,10 March 2025

Gentian Diagnostics is pleased to announce the launch of the GCAL® Calprotectin
Immunoassay with Beckman Coulter Diagnostics to its clinical chemistry
platforms. This collaboration illustrates our commitment to enhance diagnostic
efficiency for improved treatment decisions.

The Gentian GCAL® Calprotectin Immunoassay enables precise measurement of
calprotectin in human plasma and serum. Circulating calprotectin is widely
recognized as a sensitive biomarker for detection and assessment of inflammation
across a broad range of diseases. This makes it a valuable tool in numerous
inflammatory and rheumatic diseases as well as in detection and risk assessment
of the inflammatory response in infections, highlighting its broad utility in
clinical practice.

"We are pleased to officially announce that Beckman Coulter Diagnostics, a
leader in the field of clinical diagnostics, is launching our GCAL® assay," says
Matti Heinonen, CEO of Gentian Diagnostics. "This partnership builds on our
long-standing relationship with Beckman Coulter and marks a significant
milestone in our commitment to advancing market development for circulating
calprotectin. By combining our innovative GCAL® assay with Beckman Coulter's
industry expertise and reach, we are poised to empower healthcare professionals
with more accurate and timely diagnostic tools, enhancing patient care and
outcomes."

About Gentian Diagnostics
Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in
vitro diagnostic reagents. Gentian’s expertise and focus lies within homogenous
immunoassays, specifically infections, inflammations, kidney failures and
congestive heart failures. By converting existing and clinically relevant
biomarkers to the most efficient automated, high-throughput analyzers, the
company contributes to saving costs and protecting life. Gentian is
headquartered in Moss, Norway, serving the global human and veterinary
diagnostics markets through sales and representative offices in Sweden, USA, and
China. For more information, please visit www.gentian.com.

IR Contact:
Njaal Kind, CFO
njaal.kind@gentian.no
+47 919 06 525 (mobile)

More information:
Access the news on Oslo Bors NewsWeb site

640821_2025 03 10 PR GCAL BC.pdf